Pacira Pharmaceuticals (PCRX) PT Lowered to $37 at RBC Capital

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Pacira Pharmaceuticals (PCRX) PT Lowered to $37 at RBC Capital

Pacira Pharmaceuticals (PCRX) PT Lowered to $30 at Jefferies

August 1, 2024 3:59 PM EDT

Jefferies analyst Glen Santangelo lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $30.00 (from $36.00) while maintaining a Buy rating.

The analyst comments "Updating model to reflect 2Q results. Overall, we think NT results remain overshadowed by the pending court ruling... More

Pacira Pharma (PCRX) Tops Q2 EPS by 20c; offers guidance

July 30, 2024 5:26 PM EDT

Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.89, $0.20 better than the analyst estimate of $0.69. Revenue for the quarter came in at $178 million versus the consensus estimate of $173.52 million.

GUIDANCE:

Pacira Pharma sees FY2024 revenue of $680-705 million, versus the consensus of... More